Niagen Bioscience (NAGE) EBIAT (2016 - 2025)
Niagen Bioscience (NAGE) has disclosed EBIAT for 16 consecutive years, with $4.1 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 42.44% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.4 million through Dec 2025, up 103.3% year-over-year, with the annual reading at $17.4 million for FY2025, 103.3% up from the prior year.
- EBIAT for Q4 2025 was $4.1 million at Niagen Bioscience, down from $4.6 million in the prior quarter.
- The five-year high for EBIAT was $7.2 million in Q4 2024, with the low at -$8.9 million in Q3 2021.
- Average EBIAT over 5 years is -$1.1 million, with a median of -$972000.0 recorded in 2022.
- The sharpest move saw EBIAT tumbled 110.11% in 2021, then soared 24160.0% in 2025.
- Over 5 years, EBIAT stood at -$5.3 million in 2021, then surged by 73.37% to -$1.4 million in 2022, then soared by 108.04% to $114000.0 in 2023, then skyrocketed by 6197.37% to $7.2 million in 2024, then plummeted by 42.44% to $4.1 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at $4.1 million, $4.6 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.